Generate Biomedicines, Inc. filed a current report on Form 8-K on August 25, 2026, disclosing that draft copies of three clinical trial posters accepted for presentation at the European Respiratory Society Congress 2026 were inadvertently made publicly available via the ERS website before the applicable embargo expired.

Key Highlights

  • Inadvertent early release: Three draft posters were made publicly available on the ERS website before the embargo the company believed would run until 6:01 p.m. Eastern time on September 7, 2026.
  • ERS Congress 2026: The posters were accepted for presentation at the European Respiratory Society Congress 2026, scheduled for September 5-9, 2026.
  • GB-0895 anti-TSLP program: All three posters relate to GB-0895, described in the filing as a next-generation anti-TSLP monoclonal antibody under clinical investigation.
  • Indications covered: The posters address severe uncontrolled asthma (including two Phase 3 studies, SOLAIRIA-1 and SOLAIRIA-2) and adults with COPD.
  • Final posters furnished: As a precautionary measure, the company attached final poster versions as Exhibit 99.1, furnished under Regulation FD (Item 7.01).
  • Emerging growth company: Generate Biomedicines, Inc. is designated an emerging growth company as defined under applicable securities regulations, according to the filing.

Generate Biomedicines Reports Early Disclosure of GB-0895 Clinical Data

According to the filing, Generate Biomedicines, Inc. (NASDAQ:GENB), headquartered at 101 South Street, Suite 900, Somerville, Massachusetts, submitted three posters to the European Respiratory Society Congress 2026, scheduled for September 5-9, 2026. The company disclosed that draft copies of those posters were inadvertently published on the ERS website before the embargo period expired. The company stated it believed the embargo would remain in effect until 6:01 p.m. Eastern time on September 7, 2026.

The three posters all pertain to GB-0895, which the filing describes as a next-generation anti-TSLP antibody. One poster is titled "GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients." A second poster covers SOLAIRIA-1 and SOLAIRIA-2, described in the filing as "Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma." A third poster addresses GB-0895's pharmacological activity in adults with COPD, described in the filing as demonstrating "potent and sustained pharmacological activity."

The company stated it furnished the final poster versions as Exhibit 99.1 as a precautionary measure. The filing notes that the information provided under Item 7.01, including the exhibit, "is intended to be furnished and shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act of 1934." The report was signed by Jason Silvers, President and Chief Financial Officer, on August 25, 2026.

What Was Disclosed

Generate Biomedicines disclosed, via an 8-K filed August 25, 2026, that three clinical posters related to its GB-0895 anti-TSLP program were unintentionally released on the ERS website before the embargo expired, and the company furnished the final versions as an exhibit under Regulation FD.